Could a common diabetes pill protect your heart?

NCT ID NCT07614230

Recruiting now Disease control Sponsor: Junjie Yang Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether dapagliflozin, a diabetes medication, can slow or reverse plaque buildup in the heart arteries of people with type 2 diabetes. About 144 adults with stable heart disease will take either the drug plus standard care or standard care alone for 18 months. Researchers will use CT scans to measure changes in plaque and inflammation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dapagliflozin
What this could lead to: If successful, this could show that dapagliflozin helps slow or stop plaque buildup in heart arteries, reducing heart attack risk in people with type 2 diabetes.
What could go wrong: This is a relatively small, early-phase trial (144 participants) testing a secondary effect of an existing drug. The results may not confirm benefit, and side effects like dehydration or infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis coronary artery disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATHEROSCLEROSIS CORONARY ARTERY DISEASE TYPE 2 DIABETES MELLITUS (T2DM)

Contacts and locations

Locations

The First Medical Center of Chinese PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, China
The Sixth Medical Center of Chinese PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.